Hims & Hers stock plummeted 26% after the FDA resolved the semaglutide shortage, impacting their compounded weight loss drug business. Hims & Hers faces a significant revenue risk, as the FDA’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback